-
Binding Is the Easy Part(Post)
An antibody–drug conjugate is not a targeted drug. It is a delivery problem with an antibody bolted to the front of it. Binding is the easy part, and it is almost never the part that fails. What deci
Kreuzreaktivität ELISA: Praxisleitfaden für Forschende(Post)Kreuzreaktivität ELISA: Praxisleitfaden für Forschende Kreuzreaktivität im ELISA bedeutet, dass ein Antikörper an ein strukturell ähnliches Nicht-Ziel bindet und dadurch falsch-positive oder verfälsc
DNA Origami in the Brain: How Nanoscale Structural Folding Governs Neural Development(Post)Imagine a world where we can fold the very fabric of life into microscopic machines, guiding the growth of a single neuron with the precision of a master architect. This isn't science fiction; it is
CAR-T Cell Signalling Pathway: Costimulation, Output and Assays(Post)A chimeric antigen receptor is a synthetic protein wired into a real signalling pathway. The extracellular half is an antibody fragment; everything below the membrane is borrowed from the T-cell rece
After Tocilizumab, IL-6 Goes Up. That Is the Drug Working.(Post)Tocilizumab reverses cytokine release syndrome within hours, and it never touches the cell that started it. That sentence contains the whole mechanism. The trigger is a T cell — engaged by a CAR, a b
Tocilizumab (Actemra®) in COVID-19 Treatment(Post)Tocilizumab (Actemra®) in COVID-19 Treatment What is Tocilizumab? Tocilizumab, also called atlizumab, is an immunosuppress
Governing the Fate of Stem Cells With Transcription Factors(Post)The intricate process of stem cell differentiation and self-renewal is a cornerstone of developmental biology and regenerative medicine. At the heart of this complex regulatory mechanism are trans
Regulatory T Cells and the IL-2 Paradox(Page) The Interferonopathies and the Self-DNA Problem(Page) Senescence, the SASP and Immunosurveillance(Page) Ferroptosis and Immunogenic Cell Death(Page) Galegenimab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli
Spike-Recovery-ELISA: Protokoll, Berechnung und Akzeptanzgrenzen(Post)Spike-Recovery-ELISA: Protokoll, Berechnung und Akzeptanzgrenzen Spike-Recovery prüft, ob Ihre Probenmatrix die ELISA-Messung verfälscht. Sie versetzen eine bekannte Menge Antigen in Ihre Probe und p
The Rise of Alpha-Emitting Radiopharmaceuticals: A New Era in Targeted Cancer Therapy(Post)Imagine a microscopic sniper, capable of delivering a lethal blow to a single cancer cell while leaving its healthy neighbors virtually untouched. This is the promise of targeted alpha therapy, a rev
Pathological functions of IL-33/ST2 in IBD and Cancer(Post)By Charlotte O'Donnell PhD < As IL-33/ST2 is such a potent inducer of inflammation, it is not surprising that dysr
Antibody Sampler Packs(Page)Antibody Sampler Packs | 50 Pathway Panels | Assay Genie
Targeting Immune Checkpoints as Cancer Therapy(Post)The advent of immune checkpoint targeting marks a significant milestone in the oncological field, offering a beacon of hope for patients battling cancer. This innovative approach leverages the bod
B-Cell Depletion: Why Anti-CD20 Spares the Antibody(Post)You can remove almost every B cell from an animal and barely move its antibody titre. That is not a failed experiment — it is the expected result, and it follows from one fact: CD20 is switched off a
Unconventional T Cells: Already Armed, and No MHC Required(Post)Most immunology is written as though a T cell must first be told what to look for. Three lineages did not read that memo. γδ T cells, invariant NKT cells and MAIT cells leave the thymus with their ef
Delete Every Microglial Cell, Then Ask What Changed(Post)Block one receptor and more than 90% of the microglia in a mouse brain are dead within a week. Not impaired — gone. Stop the block and they come back, repopulating from the survivors within another w